DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation1 article · 1 high

USP

Every DSRV article whose Regulatory Snapshot cites USP: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under USP?
1 DSRV article cite USP. Enforcement cases behind them: FDA CGMP warning letters posted June 2, 2026: Revlon Group Holdings LLC, Umendra Life Sciences Private Limited, Shantou Qiwei Industry Co. Ltd., Laboratorios Dr. Collado S.A., Zydus Lifesciences Limited (component control/talc-asbestos cluster). Macau-Union Pharmaceutical Limited WL 724506, issued May 29, 2026 (release testing/microbiological/sub-potency/import alert). Inspection exposure across them: 1 high.
What does DSRV recommend for USP?
From the newest article (COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.): FDA enforcement is drawing a bright line between documented testing activity and defensible quality evidence. COAs document supplier claims; they do not document manufacturer verification. Your incoming testing program must stand independently. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readHigh exposurecited as a tag

    COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.

    Five CGMP warning letters in one posting cycle. Five manufacturers. The common thread: treating a supplier certificate of analysis as the endpoint of component verification instead of one data point in it. FDA's June 2026 cluster makes the distinction explicit.

    Case
    FDA CGMP warning letters posted June 2, 2026: Revlon Group Holdings LLC, Umendra Life Sciences Private Limited, Shantou Qiwei Industry Co. Ltd., Laboratorios Dr. Collado S.A., Zydus Lifesciences Limited (component control/talc-asbestos cluster). Macau-Union Pharmaceutical Limited WL 724506, issued May 29, 2026 (release testing/microbiological/sub-potency/import alert).
    DSRV take
    FDA enforcement is drawing a bright line between documented testing activity and defensible quality evidence. COAs document supplier claims; they do not document manufacturer verification. Your incoming testing program must stand independently.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under USP. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about USP

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.